TrialThe oncologist2017

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

Johanna C Bendell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.